We have previously reported a newly discovered congenital disorder of neutrophil adhesion, leukocyte adhesion deficiency syndrome type 2 (LAD II). The clinical manifestations of this syndrome are similar to those seen in the classic leukocyte adhesion deficiency syndrome, now designated type 1 (LAD I), but the two syndromes differ in the molecular basis of their adhesion defects. LAD I is caused by a deficiency in the CD18 integrin adhesion molecules while LAD II patients are deficient in expression of sialyl-Lewis X (SLe'), a carbohydrate ligand for selecting. In this report we demonstrate that neutrophils from a LAD II patient bind minimally or not at all to recombinant E-selectin, purified platelet P-selectin, or P-selectin expressed on histamine-activated human umbilical vein endothelial cells, but have normal levels of L-selectin and CD11b/CD18 integrin, and adhere to and migrate across endothelium when CD11b/CD18 is activated. We compare LAD I and LAD II patient neutrophil function in vitro, demonstrating that integrin and selectin adhesion molecules have distinct but interdependent roles in neutrophil adhesion during an inflammatory response. (J. Clin. Invest. 1995. 96:2898-2906
Introduction
Recruitment of neutrophils from the blood stream to extravascular sites of inflammation is a critical event in host defense against bacterial infection and in the repair of tissue damage. In addition, under some circumstances, neutrophil accumulation may contribute to vascular and tissue injury. Studies by intravital microscopy dating back to the 19th century have identified a complex but coordinated sequence of events involved in neutrophil emigration ( 1) . In response to extravascular stimuli such as bacterial-derived chemoattractants, or endogenous lipid and peptide mediators generated at sites of infection or tissue damage, leukocytes are first observed to "roll" along the vessel wall adjacent to the site of inflammation. This rolling was described by Atherton and Bom (2) to shear forces produced by blood flow and adhesive forces between the leukocyte and endothelium. Some of the rolling cells subsequently adhere firmly or "stick", then diapedese between endothelial cells, and migrate through the subendothelial matrix to the site of inflammation. Defects at any point in this cascade of events will impair emigration.
As with other questions in biology, important insights into the molecular basis of leukocyte adherence to endothelium during the process of migration come from studies of genetic deficiency syndromes. The leukocyte adhesion deficiency syndrome type 1 (LAD I)' results from a congenital deficiency of the leukocyte P2 integrin receptor complex CD1 1 /CD 18 on the cell surface (3, 4) . Patients with LAD I syndrome exhibit a profound defect in neutrophil and monocyte emigration to extravascular sites of inflammation. Studies in vivo (5, 6) and in vitro (7, 8) demonstrate that CD1 1 /CD 18 and its endothelial cell ligands including intercellular adhesion molecule-I (ICAM-1; CD54) are necessary for firm neutrophil adherence and transendothelial migration. However, leukocyte rolling along the vessel wall in vivo (6) and neutrophil adherence to endothelium in vitro (9) under conditions of physiologic shear forces were found not to be dependent upon CD11/CD18. Instead, multiple studies in vivo and in vitro indicate that the initial adhesive interaction between leukocytes and the vessel wall, manifested by rolling, is mediated primarily by selectin receptors and their glycoconjugate ligands (reviewed in references 10 and 11). Shear-resistant adhesion mediated by selectins promotes the initial slowing of leukocytes allowing subsequent engagement of integrin receptors and firm adhesion. Consequently, defects in selectin-dependent adhesion should also result in impaired neutrophil emigration to tissue. Etzioni et al. described two patients with a congenital defect of neutrophil adhesion resulting from a generalized fucose deficiency, and this syndrome has been designated LAD type 2 (LAD II) (12) . In the initial report, it was shown that neutrophils from the LAD II patients did not express sialyl Lewis X (SLex; CD15s), a fucose-containing glycoconjugate ligand for E (CD62E) -, P (CD62P) -, and L (CD62L) -selectins (13) (14) (15) , and failed to bind to interleukin-l-treated endothelial cells expressing E-selectin. In the studies reported here, we extend these observations, demonstrating that neutrophils from a LAD H patient bind minimally or not at all to recombinant E-selectin, purified platelet P-selectin or P-selectin expressed on histamine-activated human umbilical vein endo-whole blood by repeated lysis with cold red cell lysing solution (NH4Cl 168 mM, KHCO3 10 (23) .
Preparation of histamine-or TNF-activated HUVEC adherence assay plates. The histamine-activated HUVEC adherence assay was performed essentially as described by Lorant et Preparation ofpurified P-Selectin assay plates. P-selectin was prepared from solubilized platelet membranes essentially as described by Moore et al. (27) . P-selectin was purified from the supernatant of homogenized platelets by immunoaffinity chromatography on anti-P-selectin mAb PB 1.3 with 50 Ml/well of 3 ag/ml P-selectin in DPBS, then washed and blocked as for E-selectin plates above.
Adherence assays. Peripheral blood was obtained by venipuncture from healthy donors and patients with leukocyte adhesion deficiency syndromes (LAD I patient [7] and LAD II patient [12] ) after informed consent according to protocols approved by the Human Subjects Review Boards of the University of Washington and the Rambam Medical Center. The blood was collected in syringes containing heparin (10 U/ml) and the neutrophils were isolated as previously described (28) . Isolated neutrophils were washed three times in PBS and resuspended to 2 x 107/mI in PBS containing 5 mM glucose, 0.7 mM CaCl2, and 0.7 mM MgCl2 except where otherwise indicated.
Assay plates were washed twice in HBSSg/BSA and then incubated with 100 Ml of buffer containing antibodies at the concentrations indicated in the figure legends and/or PMA at 10-7 M where indicated. Neutrophils (5 X 105 in 50 ML of HBSSg per well) were added and allowed to settle for 5 min (activated HUVEC plates) or 10 min (purified E-or P-selectin plates). The plates were then washed three times by inverting and refilling with 200 Ml of HBSSg/BSA using a multichannel pipette. Neutrophil adherence was quantitated by spectrophotometric analysis of myeloperoxidase (29) .
Neutrophil migration assays. 
Results
Expression of cell adhesion molecules and surface markers on LAD II leukocytes. LAD II patient leukocytes were examined for their expression of surface markers associated with cellular adhesion functions. As previously reported (12), LAD II neutrophils were deficient in expression of the Lex (CD15) antigen (7C3 mAb) and the SLex (CD15s) antigen (CSLEX-1 mAb) ( Table I and Fig. 1 ). We have extended this finding by demonstrating that neutrophils from both parents of this patient express normal levels of Lex and Slex (Table I ). In addition, peripheral blood mononuclear leukocytes of the LAD II patient were deficient in expression of SLex (Table I) .
In contrast to SLex expression, both LAD II and parental neutrophils had normal levels of the integrin subunits CDllb (OKM-I mAb) and CD18 (60.3 mAb). Patient neutrophils also expressed normal levels of CD43 (BS1 mAb), CD66 (Gran/ 10 mAb), CD16 (Leu llb mAb), and CD45RO (UCHL-1 mAb) (Table I) . Upon activation by PMA, LAD II neutrophils exhibited increased binding of CD1 lb (Fig. 1 ) and CD66 mAbs (Table I ) and reduced binding of CD43 mAb (Table I) , comparable to that seen with normal donor cells. Of particular interest was the normal level of L-selectin (CD62L; Leu 8 mAb) seen on LAD II neutrophils and the down-regulation of its expression induced by PMA activation, comparable to that observed with normal donor cells (Fig. 1) .
Peripheral blood mononuclear cells from a LAD II patient expressed normal levels of the memory T cell marker CD45RO (UCHL-1 mAb), but failed to bind HECA-452 mAb, a marker for skin-homing T lymphocytes also found on neutrophils (30, 31) , that recognizes sialyl-Lewis A (SLea) as well as SLeX (22) (Table I) LAD II patient and a normal control were examined for their ability to bind to purified platelet-derived P-selectin and to purified recombinant E-selectin. As seen in Fig. 2 , normal donor neutrophils bound to P-selectin in the presence but not in the absence of divalent cations. This adherence was inhibited by anti-SLex mAb (A490 = 1.05 vs 0.78, P < 0.05). LAD II neutrophils did not bind to P-selectin in the presence or in the absence of divalent cations (Fig. 2) . Similarly, normal donor neutrophils bound to recombinant E-selectin in the presence but not in the absence of divalent cations (Fig. 2) . This adherence was inhibited by anti-SLex mAb (A490 = 0.88 vs 0.42, P < 0.01). Patient neutrophils bound weakly to recombinant E-selectin in the presence, but not in the absence of divalent cations (Fig. 2) . This small amount of adherence was not inhibited significantly by SLeX mAb (A490 = 0.16 vs 0.12, P > 0.1).
LAD II neutrophils bind minimally to TNF-or to histamineactivated HUVEC but can be activated by PMA to adhere to HUVEC. To determine the effect of SLeX deficiency on neutrophil binding in the presence of receptors for the /2 integrins LFA-1 and Mac-i, we examined neutrophil adherence to TNFand to histamine-activated HUVEC. Normal donor neutrophils bound significantly to TNF-activated HUVEC (Fig. 3) and to histamine-activated HUVEC (Fig. 4) . In each case the binding was partially blocked by addition of CD18 mAb (60.3) or of anti-SLex mAb (CSLEX-1), and there was an additive effect when the two mAbs were used in combination. Isotypematched, neutrophil-binding control mAbs (JP34-10 for 60. 3 and CDw17 for CSLEX-1) did not inhibit binding of control neutrophils (P > 0.1 in each case). Complete blocking of adhesion was achieved when higher concentrations of CSLEX-1 mAb were used (10 jig/ml); however, some agglutination of neutrophils occurred at this concentration of mAb. These results indicate that adherence of normal neutrophils to activated endothelial cells involves both SLex binding to E-and P-selectins and /2 integrins binding to their receptors.
LAD I neutrophils also bound well to histamine-activated HUVEC. As expected, LAD I neutrophil adherence was not inhibited by CD18 mAb but was inhibited by anti-SLex mAb (Fig. 4) . In these static assays LAD II neutrophils bound minimally to TNF-activated HUVEC (Fig. 3) or to histamine-activated HUVEC (Fig. 4) . In both cases this small amount of binding was completely blocked by CD18 mAb but not by antiSLeX mAb.
Phorbol myristate acetate treatment of LAD H neutrophils induced marked adhesion to unactivated endothelium as it did for normal donor neutrophils (Fig. 4) . The PMA-induced binding of control and LAD II neutrophils was completely blocked by CD18 mAb (Fig. 4) . In a separate experiment control isotype-matched mAb did not inhibit PMA-induced adherence of control neutrophils (A490 = 2.16 vs 2.19, P > 0.1 ) while CD18 mAb was very effective (A490 = 2.16 vs 0.23, P < 0.01, n = 5). LAD I neutrophils increased adherence slightly with PMA treatment, but CD18 mAb had no effect on this small amount of adherence (Fig. 4) .
LAD II neutrophils migrate through endothelial monolayers (Fig. 6 ). In contrast, LAD I neutrophils (Fig. 6 ) and normal donor and LAD II neutrophils that had been treated with the CD18 mAb 60.3 (data not shown) failed to spread.
Discussion
LAD II is a newly described congenital disorder of neutrophil adhesion. Like the classic leukocyte adhesion deficiency syndrome, now designated type 1 (LAD I), LAD II is characterized by neutrophilia, recurrent bacterial infections, decreased neutrophil motility and adhesion in vitro (12) , and defective neutrophil emigration in vivo as assessed by skin chamber and skin window (32) . In contrast to LAD I cells, neutrophils from the two known patients with LAD II syndrome were shown to express normal levels of CD11/CD18. Instead, LAD U cells were found to be deficient in SLeX, a fucose-containing carbohydrate moiety, and were unable to bind to E-selectin expressed on interleukin-1,B-activated human umbilical vein endothelial cells. These results suggested that the adhesion deficiency in these patients was caused by a lack of carbohydrate ligand, SLe , which is required for selectin-mediated neutrophil adhesion to endothelial cells (33) (34) (35) . In gens including L-selectin and the f2 integrin subunits CD1lb and CD18. The finding that patient cells exhibited normal levels of L-selectin is of considerable interest in view of the fact that L-selectin on neutrophils has been shown to present SLex for recognition by E-and P-selectins (37) , and this function is absent in LAD II cells. L-selectin has also been demonstrated to recognize a structure induced on cytokine-activated endothehlum in vitro (38) , and on inflamed endothelium in the systemic microcirculation in vivo (39 Figure 3 . Neutrophil adherence to TNF-activated HUVEC. Purified neutrophils from a normal donor or the LAD II patient were incubated for 5 min on HUVEC monolayers which had been activated for 4 h with recombinant human TNF (2 ng/ml) or treated with control medium. In some wells, the CD18 mAb (60.3) (20 jig/ml) or anti-SLex mAb (CSLEX-1) (6 jig/m1) was present in the wells during the neutrophil incubation. The plates were washed and adherence was quantitated by spectrophotometric analysis of the neutrophil-specific enzyme myeloperoxidase as described in Methods. *P < 0.05 or * *P < 0.01, for adherence of mAb-treated neutrophils compared to untreated neutrophils to TNF-activated HUVEC. *P < 0.05 or 11P < 0.01, for adherence to TNF-activated HUVEC compared to basal adherence. were incubated on HUVEC monolayers grown to confluence in transwells. In experiment 1, neutrophils from a normal donor or a LAD II patient were either pretreated with medium alone or medium containing the CD18 mAb (60.3) (20 jig/ml). In experiment 2, only untreated LAD II cells were tested. In both experiments f MLP ( 10 -7 M) was placed in the lower chamber of the indicated samples to act as chemoattractant. Migration was assessed following a 90-min incubation at 37°C by determining 51Cr-cpm present in the lower well as described in Methods. * P < 0.05 or * *P < 0.01, for transmigration to FMLP compared to basal transmigration. 11P < 0.01, for mAb-treated neutrophil transmigration compared to untreated neutrophil transmigration.
peripheral blood T and B cells (43) . Although not directly tested, binding of these LAD II mononuclear cells to P-or Eselectin would likely be decreased, and emigration in vivo to sites of immune reaction may consequently be reduced. Similarly, monocyte emigration would also be expected to be affected as peripheral monocytes express SLeX (44) , and bind to E-and P-selectins (45, 46) . Indeed, skin window studies in this patient demonstrate a marked reduction in monocyte emigration (32) . Picker et al. (31 ) reported that the HECA-452 mAb identified skin-homing memory T cells that bind to E-selectin. The traffic of these particular memory T cells to immune-reactive dermal sites would also likely be impaired in LAD II syndrome. In a previous report (12) , LAD H neutrophils were shown not to bind to E-selectin induced on HUVEC monolayers by interleukin-1,. In the current study, we examined neutrophil adherence to TNF-activated HUVEC monolayers under static assay conditions, and found that LAD II neutrophils bound minimally to cytokine-activated HUVEC. These results with Eselectin expressed on HUVEC were confirmed by demonstrating that LAD II neutrophils showed a marked reduction in calcium-dependent binding to recombinant E-selectin.
The marked reduction in LAD II neutrophil adhesion to cytokine-or histamine-treated HUVEC monolayers or to purified selectins suggests that efficient binding requires the interaction of the lectin domain of the selectin receptor with a fucosecontaining glycoconjugate ligand(s) on the neutrophil. Thus, potential selectin receptor interactions with sulfatides which have been previously described (47) are not alone sufficient for adhesion under these static assay conditions. The high affinity (12, 36) .
Since CD1lb has been shown to express Lex (51), we considered the possibility that the defect in fucose metabolism somehow affected CD 1 /CD 1 8 function. CD1 1 /CD 18 adhesive function was tested directly in several static adhesion assays. When activated by phorbol ester, LAD II neutrophils showed a marked increase in adhesion to HUVEC, comparable to that observed with normal donor neutrophils. Patient cells also migrated across HUVEC monolayers in response to FMLP, a CD1 1 /CD1 8-dependent function (7 ) . This latter result in vitro is in keeping with in vivo studies of von Andrian et al. (40) . These investigators examined the interaction of LAD II neutrophils with endothelium in inflamed rabbit mesenteric vessels, and found that LAD II neutrophils were able to emigrate from the vessel lumen to tissue when flow (i.e., shear force) was reduced. We also examined CD1 1/CD 18-mediated neutrophil spreading on phorbol ester-treated glass cover slips. The (52) . It is possible that L-selectin recognition of an SLex-like fucose-containing ligand is involved in the initial stabilization of the cell-cell aggregates, before adhesion strengthening mediated by the interaction of the 62 integrins with its as yet unidentified ligand (53) .
Our studies show a severe reduction in binding of LAD II neutrophils to E-and P-selectins, a finding consistent with the marked impairment in neutrophil emigration to skin windows or chambers reported in the LAD II patient (32) and to inflamed peritoneum observed in E-selectin null mice treated with an anti-P-selectin mAb (54) . Importantly, although the LAD II patients have a severe defect in the function of two selectin pathways, their clinical course to date has been relatively mild when compared to that of patients with complete 62 integrin deficiency. Both syndromes manifest themselves in the first few days of life, but with different symptoms. In LAD I delayed separation of the umbilical cord with omphalitis is typical. In LAD II, pneumonia with very marked neutrophilia in the first week of life was observed in both patients. During infancy and early childhood recurrent pneumonia and otitis media occurred in the two LAD II patients. These were not life-threatening events and were usually treated in the outpatient clinics. Several episodes of mild to moderate skin infections without obvious pus were also observed. In the last four years the frequency of infections has decreased and the children are off prophylactic antibiotics, but marked neutrophilia persists. Overall, the infections in LADII appear to be comparable to the moderate rather than the severe phenotype of LAD I. We speculate that the ability of LAD H neutrophils to adhere and transmigrate via /2 integrins under conditions of reduced shear forces (40) may allow some neutrophils to emigrate at sites of severe inflammation where flow may be impaired, thereby allowing some level of neutrophil defense against bacterial infection.
In summary, this report has provided further characterization of neutrophil function in the newly described LAD II syndrome. The major findings of our studies are: (a) SLex and other fucose-containing antigens are absent on both neutrophils and mononuclear leukocytes; (b) there is a marked defect in neutrophil binding to P-selectin as well as to E-selectin; (c) neutrophil surface antigens modulate normally after activation; and (d) CDl 1 /CD18 adhesive functions are intact. Studies of leukocyte function in LAD I syndrome have proven invaluable in defining the role of /32 integrin receptors in leukocyte-endothelial interactions, and it is anticipated that similar insights into selectin receptor biology will be gained from further careful investigation of the LAD H syndrome.
